In News

Follow this topic

Bookmark

Record learning outcomes

Ustekinumab (Stelara) is now available for moderate-to-severe plaque psoriasis in patients aged 12 years and older, who are inadequately controlled by, or intolerant of, other systemic therapies or phototherapies.

Plaque psoriasis is a chronic autoimmune disease that is believed to affect 0.5 to two per cent of the general population during childhood and adolescence.